Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

Sanderling Ventures Leads $12M Series A In Drug Developer

by posted 2years ago 2153 views
San Francisco-based Glycomine, a developer of orphan drugs for serious rare monogenic disorders of metabolism, has raised $12 million in Series A financing. Sanderling Ventures led the round with participation from other investors that included Chiesi Ventures. In conjunction with the funding, Dr. Peter McWilliams, a managing director at Sanderling Ventures and Giacomo Chiesi, a managing partner at Chiesi Ventures, have been added to Glycomine’s board of directors.